Key clinical point: Serum 25(OH)D levels are associated with a modest decrease in relapse rate and radiological inflammatory activities in patients with early relapsing multiple sclerosis (MS).
Major finding: Each 25 nmol/L increase in serum 25(OH)D levels is associated with a decrease in clinical relapse rate (risk ratio [RR], 0.90), gadolinium-enhancing lesions (RR, 0.69), new/enlarging T2 lesions (RR, 0.86), and new active lesions (RR, 0.81) in the magnetic resonance imaging.
Study details: Meta-analysis of 13 studies including 3,498 patients.
Disclosures: No study sponsor was identified .
Citation: Martínez-Lapiscina EH et al. J Neurol Sci. 2020 Jan 25. doi: 10.1016/j.jns.2020.116668.